Maxcyte Share Discussion Threads

[trident5] 26/7/2021 13:45

"something like $250 mil in the bank".
Presumably they're not confident of generating operational cash flow any time soon, if they're building such a hefty bank balance.

[nimbo1] 26/7/2021 13:26

Exciting times, when I started buying maxcyte Dec 2019 the nasdaq listing was a distant dream... they had no cash in the bank and were still funding the loss making carma.

Now we have some of the worlds best US healthcare investors onboard and a nasdaq ipo happening near recent highs which will given them something like $250 mil in the bank.

I don't know what comes next but its been an interesting ride so far.

[adamb1978] 26/7/2021 13:01

In the current market, I think it'll price near the top of the range, which is around £10 per share

[trident5] 26/7/2021 12:28

Quite a dilution then.

[nimbo1] 26/7/2021 12:05

I have no source - they are the book runners and maxcyte were going to raise $100 mil... and now its been lifted to $150 - assuming it prices near the top end of the range

[mg1982] 26/7/2021 11:57

nimbo1 how do you know cowen advised it to be increased from 100 to 150? Do you have a source please?

[nimbo1] 26/7/2021 11:53

This is where some smaller holders get scared into selling - i would think given it seems someone (Cowen?) advised the amount raised to be increased from 100 to 150 would indicate good demand and it will therefore price towards the top of the range before the price is driven higher in the open market. We'll see if it plays out like that. GL.

Renx followed the same format but with a steeper discount. Just the way the game is played.

[adamb1978] 26/7/2021 11:41

Only 12m shares too....should be pretty illiquid. Mind you, the company doesnt need the money at the moment so pleased its only a small volume

[adamb1978] 26/7/2021 11:39

$11.50 to $13.50 offer price....priced to bounce?

[pob69] 26/7/2021 11:21

The 400 page Nasdaq ammended IPO offer document is available via

[multibagger] 18/7/2021 14:27

The Times had an article on AIM and Inheritance Tax implications yesterday (Sat, 17th Jul). As per the article (and what I imagine most of us know) though many AIM stocks will fall outside IHT in the normal course of events if held for 2 years, dual listed companies are not exempt and would be caught in the IHT net.

This was something I was unaware of. So for some, NASDAQ listing could be a mixed blessing in the long term....


Excerpt from the above mentioned article:

"....The nitty-gritty


Not all companies listed on the Aim qualify for business relief, and therefore it is not a given that your Aim shares will be free of IHT.

To qualify for business relief, the company must be engaged in continuing trade and not make most of its income “passivelyR21;, for example from investments or property sales. Some oil and mining companies do not qualify because some of their revenue comes from the sale of property assets. Financial firms that make money from interest or growth on investments do not benefit from business relief either.

Whether a company qualifies for relief can change, depending on the ins and outs of their business dealings in a given year. It is difficult to pin down exactly how many companies on Aim qualify for the relief, but two thirds to three quarters do.

Business relief is assessed upon death, rather than when you took out the investment, so it depends on whether the companies you are invested in qualify for IHT relief in the year you die. To qualify, shares must also be held for at least two years before you die and they cannot be dual-listed on another recognised stock market, such as an overseas listing. If the shares do qualify, they are 100 per cent free from IHT and do not count towards your estate.

IHT is charged at 40 per cent. You get a £325,000 IHT allowance, which increases by £175,000 if you are passing on your main residence to a direct descendant. The £325,000 allowance, unchanged since 2009, was frozen in the budget in March so will not increase until at least 2026. It is catching more and more families in the IHT net as UK property prices increase...."

[mysteronz] 18/7/2021 14:09

Excuse ignorance but do MXCT say what they plan to do with the funds generated through this NASDAQ listing? Recent fundraises should get them to self funding.

I know they need to offer shares as part of NASDAQ listing but curious to know what they are going to do with the $

[cooltools] 16/7/2021 10:59

Seems related but doesn't look MXCT - would be pleased if it was!

Instrument at 1:45



Original press release:

[pob69] 15/7/2021 08:49

Apis Capital deep-value-fund-2q21-commentary/

"....Considering MaxCyte is a largely undiscovered name among U.S. investors with limited broker coverage as well as the historical precedent of companies that have followed a similar path to a U.S. listing, we fully anticipate the listing to be a strong share catalyst."

[adamb1978] 13/7/2021 14:22

Magic, thanks Russ...very kind! Thats my afternoon sorted!!

[homebrewruss] 13/7/2021 14:13

Adam, i haven't seen a pdf but this html version should be easier to read:

Actually if you print as pdf in your browser from that document it comes out pretty well.
Here's one I made earlier.. :)

[adamb1978] 13/7/2021 14:05

Has anyone seen a link to a pdf of the prospectus? The link to the doc which Dave posted a couple posts above this has odd formatting with double underlines on a lot of te text and the financial tables are messed up
Cheers

[acuere] 13/7/2021 14:01

Just bringing this thread back to the top. Nobody had posted on that other thread for 5 years until chester posted today why it had been started?????

Can we please stick to this thread.

[assagai] 13/7/2021 12:48

Chester, agreed, what's the point?

[edwardt] 13/7/2021 11:46

This has now 10 bagged for me. I have never ever had that before. Happy days!

[chester] 13/7/2021 09:43

We already have a MXCT thread. Do we need another ?

[rgmgo] 12/7/2021 11:59

The S-1 actually has some interesting projections. MXCT talks about an ongoing shift to non-viral delivery and a potential market opportunity of 140 Strategic Partner Licenses by 2026 versus 50 currently. If they maintain market share (13 SPLs today) and average customer size, that could deliver 2.8x growth in potential milestones. Nonetheless, I think you can make a case that prices above £10 are moving into more aggressive valuation territory, but I'm not sure that this is likely to matter. In line with other posters I agree that US investors now price this stock, and history suggests that they have a tolerance for much more aggressive growth assumptions than the typical UK investor.

[pob69] 09/7/2021 22:13

Things are progressing;

Form S1

MaxCyte files $100M offering through the following Bookrunners Cowen, Stifel, William Blair, BTIG and Stephens